Recon: FDA delays decision on Ascendis’ hormone disorder drug; Edwards faces EU antitrust complaint

ReconReconApproval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicySubmission and registrationUnited States